The latter two risks may be lower when using a transdermal administration of estrogen rather than an oral one, and Salubrinal solubility dmso especially so in women with a genetic predisposition of thrombosis [29, 30]. Similarly, tibolone should not be viewed as a first line therapy for osteoporosis treatment. In an RCT in elderly women suffering from osteoporosis at the hip or spine or osteopenia and radiologic evidence of a vertebral fracture, Cummings et al. [31] evaluated

tibolone (1.25 mg/day, i.e., half the conventional dosis) as compared to placebo. After a median time of 34 months of treatment, the tibolone group, as compared with the placebo group, had a decreased risk of vertebral fracture (70 cases vs. 126 cases per 1,000 person-years; RR, 0.55; 95% CI, 0.41–0.74; p < 0.001) and a decreased risk of nonvertebral fracture (122 cases vs. 166 cases per 1,000 person-years; RR, 0.74; 95% CI, 0.58–0.93; p = 0.01). Interestingly the tibolone group also had a decreased risk of invasive breast cancer (RR,

0.32; 95% CI, 0.13–0.80; p = 0.02) and colon cancer (RR, 0.31; 95% CI, 0.10–0.96; p = 0.04). However, because the tibolone group had an increased risk of stroke (RR, 2.19; 95% CI, 1.14–4.23; p = 0.02), the study was PRN1371 stopped prematurely. Although prolonged use of HRT may reduce the risk of fracture in healthy postmenopausal women, these data have to be strongly weighted against the other reported effects of HRT on disease outcomes (breast cancer risk, thromboembolic disease, risk of stroke, etc.) and with the possibility of treating women for osteoporosis with other therapeutic Histone Methyltransferase inhibitor regimens [32]. Given these possibilities, our view is that, currently, HRT should not be prescribed for osteoporosis in women who do not experience menopausal symptoms. In symptomatic women, the potential adverse effects should be explained, and the treatment should be prescribed for short periods of time. Indeed, Lekander et al. [33], using a Markov cohort simulation model and using results taken from the WHI and containing hip, vertebral, and wrist fracture, breast and colorectal

cancer, coronary heart disease, stroke, and venous thromboembolic MTMR9 events, found that it was cost-effective to treat women with menopausal symptoms with HRT and even where symptoms were mild HRT remained cost-effective [33]. The question remains unanswered whether HRT prescribed for a few years to suppress menopausal symptoms offers also long-lasting benefits for the prevention of postmenopausal bone loss and osteoporotic fracture. While most observational studies reported that past HRT users had the same osteoporosis risk as never users after a few years of HRT withdrawal, Bagger et al. [34] reported in 347 healthy postmenopausal women with normal bone mass who had earlier participated in placebo-controlled HRT trials that compared to placebo-treated women, HRT-treated women had a significantly reduced risk of osteoporotic fractures (RR = 0.48 (95% CI, 0.26–0.88)).